Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 150

Sort by

Sort Order Select

Journal Articles

HDAC11 deficiency disrupts oncogene-induced hematopoiesis in myeloproliferative neoplasms

Blood (2020) 135 (3): 191–207.

https://doi.org/10.1182/blood.2019895326

Published: 2020

Includes: Supplemental data

Journal Articles

Cell-Free DNA Genotyping Analysis in Diffuse Large B-Cell Lymphoma; The Correlation between TP53 Gene Mutation and Cereblon Gene Mutation

Hideki Uryu, MD, Yuko Mishima, MD PhD, Yuji Mishima, PhD, Masahiro Yokoyama, MD, Noriko Nishimura, MD PhD, Yoshiharu Kusano, MD, Takashi Okabe, MD, Norihito Inoue, MD, Takanori Fukuta, MD, Yuko Shirouchi, MD, Kiyohiko Hatake, MD PhD, Yasuhito Terui, MD PhD

Blood (2019) 134 (Supplement_1): 2786.

https://doi.org/10.1182/blood-2019-122920

Published: 2019

Journal Articles

Interaction of Plasmacytoid Dendritic Cells and Myeloma Cells Trigger Tumor Promoting Transcriptional Changes in Multiple Myeloma Cells

Arghya Ray, PhD, Leutz Buon, Yan Song, PhD, Dharminder Chauhan, PhD, Kenneth C. Anderson, MD

Blood (2019) 134 (Supplement_1): 510.

https://doi.org/10.1182/blood-2019-123333

Published: 2019

Journal Articles

Selective Targeting of Histone Deacetylase 11 Disables Metabolism of Myeloproliferative Neoplasms

Blood (2019) 134 (Supplement_1): 474.

https://doi.org/10.1182/blood-2019-127235

Published: 2019

Journal Articles

HDAC8 Maintain Cytoskeleton Integrity Via Homologous Recombination and Represent a Novel Therapeutic Target in Multiple Myeloma

Zuzana Chyra, PhD, Maria Gkotzamanidou, MD PhD, Masood A. Shammas, PhD, Vassilis L. Souliotis, PhD, Yan Xu, MD, Mehmet K. Samur, PhD, Aaron B. Beeler, PhD, Roman Hajek, MD, Mariateresa Fulciniti, PhD, Nikhil C. Munshi, MD

Blood (2019) 134 (Supplement_1): 4385.

https://doi.org/10.1182/blood-2019-130700

Published: 2019

Journal Articles

Gene Expression Profiling Using Nanostring™ Reveals Differences According to Location, Histology and MIPI Score in Mantle Cell Lymphoma

Diana Lucia Martínez Baquero, MD, Ken H. Young, Roberto N. Miranda, MD, L. Jeffrey Medeiros, MD, Chi Young Ok, MD

Blood (2019) 134 (Supplement_1): 5218.

https://doi.org/10.1182/blood-2019-132056

Published: 2019

Journal Articles

The Necessary for Long-Term Follow-up of Mutated Genes and Clonal Evolutions in Multiple Myeloma Combined with cfDNA Assay

Yuko Mishima, MD PhD, Yuji Mishima, PhD, Masahiro Yokoyama, MD, Noriko Nishimura, MD PhD, Yoshiharu Kusano, MD, Norihito Inoue, MD, Hideki Uryu, MD, Takanori Fukuta, MD, Yuko Shirouchi, MD, Kiyohiko Hatake, MD PhD, Yasuhito Terui, MD PhD

Blood (2019) 134 (Supplement_1): 5515.

https://doi.org/10.1182/blood-2019-122977

Published: 2019

Journal Articles

Serum Cell-Free DNA Concentration Is Predictive of Survival Outcomes and Its Genetic Mutation Analysis May Be Viable in Obtaining Pathological Information

Yuko Shirouchi, MD, Yuko Mishima, MD PhD, Yuji Mishima, PhD, Masahiro Yokoyama, MD, Noriko Nishimura, MD PhD, Yoshiharu Kusano, MD, Hideki Uryu, MD, Takashi Okabe, MD, Norihito Inoue, MD, Takanori Fukuta, MD, Kiyohiko Hatake, MD PhD, Yasuhito Terui, MD PhD

Blood (2019) 134 (Supplement_1): 1498.

https://doi.org/10.1182/blood-2019-125096

Published: 2019

Journal Articles

Development TACI and Bcma Dual-Antigen Targeted Immunotherapy for Multiple Myeloma

Jooeun Bae, PhD, Teru Hideshima, MD PhD, Mehmet Kemal Samur, PhD, Paul G. Richardson, MD, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD

Blood (2019) 134 (Supplement_1): 3138.

https://doi.org/10.1182/blood-2019-128689

Published: 2019

Journal Articles

Novel Therapeutic Rationale for Targeting HDAC1 and PIM2 in Multiple Myeloma

Takeshi Harada, MD PhD, Asuka Oda, Hiroto Ohguchi, MD PhD, Yohann Grondin, PhD, Hirofumi Tenshin, DDS, PhD, Masahiro Hiasa, DDS, PhD, Jumpei Teramachi, Masahiro Oura, MD, Kimiko Sogabe, MD, Shiro Fujii, MD PhD, Shingen Nakamura, MD PhD, Hirokazu Miki, MD PhD, Kumiko Kagawa, MD PhD, Shuji Ozaki, MD PhD, Teru Hideshima, MD PhD, Kenneth C. Anderson, MD, Masahiro Abe, MD PhD

Blood (2019) 134 (Supplement_1): 3111.

https://doi.org/10.1182/blood-2019-127679

Published: 2019

Journal Articles

Suz12 inactivation cooperates with JAK3 mutant signaling in the development of T-cell acute lymphoblastic leukemia

Michael Broux, Cristina Prieto, Sofie Demeyer, Marlies Vanden Bempt, Llucia Alberti-Servera, Inge Lodewijckx, Roel Vandepoel, Nicole Mentens, Olga Gielen, Kris Jacobs, Ellen Geerdens, Carmen Vicente, Charles E. de Bock, Jan Cools

Blood (2019) 134 (16): 1323–1336.

https://doi.org/10.1182/blood.2019000015

Published: 2019

Includes: Supplemental data

Journal Articles

SE-7552, a Highly Selective, Non-Hydroxamate Inhibitor of Histone Deacetylase-6 Blocks Multiple Myeloma Growth In Vivo

Jason A Holt, MSc, Edward P Garvey, PhD, J. David Becherer, PhD, William J Hoekstra, PhD, Robert J Schotzinger, MD PhD, Christopher M Yates, MSc

Blood (2018) 132 (Supplement 1): 3215.

https://doi.org/10.1182/blood-2018-99-113066

Published: 2018

Journal Articles

Plasmacytoid Dendritic Cells Trigger Contact-Dependent Tumor Promoting Genetic Alterations in Multiple Myeloma Cells

Arghya Ray, PhD, Leutz Buon, Yan Song, PhD, Dharminder Chauhan, PhD, Kenneth C. Anderson, MD

Blood (2018) 132 (Supplement 1): 244.

https://doi.org/10.1182/blood-2018-99-117887

Published: 2018

Journal Articles

Signatures of Histone Modification Marks and Proteins in Pediatric Acute Myeloid Leukemia: A Comparison to Adults

Anneke D. Van Dijk, Fieke W Hoff, Eveline S. de Bont, MD PhD, YIHUA QIU, Chenyue W. Hu, Amina A Qutub, PhD, Terzah M. Horton, MD PhD, Steven M. Kornblau, MD

Blood (2018) 132 (Supplement 1): 2761.

https://doi.org/10.1182/blood-2018-99-110475

Published: 2018

Journal Articles

The Rare Diseases Pilot for the 100,000 Genomes Project: Findings in Known and New Genes by Analysis of 3,549 Whole Genome Sequenced Samples from Patients and Relatives with Haematological, Haemostasis and Immune Disorders

Suthesh Sivapalaratnam, MD PhD, Nihr Bioresource

Blood (2018) 132 (Supplement 1): 504.

https://doi.org/10.1182/blood-2018-99-119068

Published: 2018

Journal Articles

Histone Deacetylase Inhibitors with or without AKT Inhibition Potentially Increase the Efficacy of Daratumumab in Multiple Myeloma By Enhancing the Antibody-Dependent Cell-Mediated and Complement-Dependent Cytotoxicity As Well As Apoptosis

Mitsuhito Hirano, MD, Yoichi Imai, MD PhD, Weng-Chit Ung, MSc, Kota Sato, MD PhD, Muneyoshi Futami, MD PhD, Arinobu Tojo, MD PhD

Blood (2018) 132 (Supplement 1): 4435.

https://doi.org/10.1182/blood-2018-99-110709

Published: 2018

Journal Articles

Efficacy of a New Small-Molecule Inhibitor of Histone Deacetylase 6 (HDAC6) in Preclinical Models of B-Cell Lymphoma and Acute Myeloid Leukemia

Blood (2018) 132 (Supplement 1): 5383.

https://doi.org/10.1182/blood-2018-99-111578

Published: 2018

Journal Articles

Combination of Momelotinib and Citarinostat Show Strong Synergistic Effect in Lymphoid Cell Lines Co-Targeting JAK2/STAT3 and HDAC6

Maria Cosenza, MS, Monica Civallero, PhD, Stefano Sacchi, MD, Samantha Pozzi, MD

Blood (2018) 132 (Supplement 1): 3506.

https://doi.org/10.1182/blood-2018-99-116468

Published: 2018

Journal Articles

Oncolytic Reovirus Is an Effective Treatment for Histone Deacetylase Inhibitor Resistant T-Cell Lymphoma

Shariful Islam, Claudia M Espitia, Ning Qu, MD PhD, Daniel Persky, MD, Jennifer S. Carew, PhD, Steffan T. Nawrocki, PhD

Blood (2018) 132 (Supplement 1): 2941.

https://doi.org/10.1182/blood-2018-99-119152

Published: 2018

Journal Articles

A Novel Role for Histone Deacetylase 10 (HDAC10) in the Regulation of PD-L1 Expression and Immune Tolerance Mediated By Antigen Presenting Cells (APCs)

Michael Wang, Bachelor of Science, Fengdong Cheng, MD, Jie Chen, PhD, Yixuan Li, PhD, Alejandro Villagra, PhD, Mitchell R. Smith, MD PhD, Edward Seto, PhD, Eduardo Martin Sotomayor, MD

Blood (2017) 130 (Supplement 1): 3561.

https://doi.org/10.1182/blood.V130.Suppl_1.3561.3561

Published: 2017

NARROW

HDAC11 deficiency disrupts oncogene-induced hematopoiesis in myeloproliferative neoplasms

Cell-Free DNA Genotyping Analysis in Diffuse Large B-Cell Lymphoma; The Correlation between TP53 Gene Mutation and Cereblon Gene Mutation

Interaction of Plasmacytoid Dendritic Cells and Myeloma Cells Trigger Tumor Promoting Transcriptional Changes in Multiple Myeloma Cells

Selective Targeting of Histone Deacetylase 11 Disables Metabolism of Myeloproliferative Neoplasms

HDAC8 Maintain Cytoskeleton Integrity Via Homologous Recombination and Represent a Novel Therapeutic Target in Multiple Myeloma

Gene Expression Profiling Using Nanostring™ Reveals Differences According to Location, Histology and MIPI Score in Mantle Cell Lymphoma

The Necessary for Long-Term Follow-up of Mutated Genes and Clonal Evolutions in Multiple Myeloma Combined with cfDNA Assay

Serum Cell-Free DNA Concentration Is Predictive of Survival Outcomes and Its Genetic Mutation Analysis May Be Viable in Obtaining Pathological Information

Development TACI and Bcma Dual-Antigen Targeted Immunotherapy for Multiple Myeloma

Novel Therapeutic Rationale for Targeting HDAC1 and PIM2 in Multiple Myeloma

Suz12 inactivation cooperates with JAK3 mutant signaling in the development of T-cell acute lymphoblastic leukemia

SE-7552, a Highly Selective, Non-Hydroxamate Inhibitor of Histone Deacetylase-6 Blocks Multiple Myeloma Growth In Vivo

Plasmacytoid Dendritic Cells Trigger Contact-Dependent Tumor Promoting Genetic Alterations in Multiple Myeloma Cells

Signatures of Histone Modification Marks and Proteins in Pediatric Acute Myeloid Leukemia: A Comparison to Adults

The Rare Diseases Pilot for the 100,000 Genomes Project: Findings in Known and New Genes by Analysis of 3,549 Whole Genome Sequenced Samples from Patients and Relatives with Haematological, Haemostasis and Immune Disorders

Histone Deacetylase Inhibitors with or without AKT Inhibition Potentially Increase the Efficacy of Daratumumab in Multiple Myeloma By Enhancing the Antibody-Dependent Cell-Mediated and Complement-Dependent Cytotoxicity As Well As Apoptosis

Efficacy of a New Small-Molecule Inhibitor of Histone Deacetylase 6 (HDAC6) in Preclinical Models of B-Cell Lymphoma and Acute Myeloid Leukemia

Combination of Momelotinib and Citarinostat Show Strong Synergistic Effect in Lymphoid Cell Lines Co-Targeting JAK2/STAT3 and HDAC6

Oncolytic Reovirus Is an Effective Treatment for Histone Deacetylase Inhibitor Resistant T-Cell Lymphoma

A Novel Role for Histone Deacetylase 10 (HDAC10) in the Regulation of PD-L1 Expression and Immune Tolerance Mediated By Antigen Presenting Cells (APCs)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only